Log In
BCIQ
Print this Print this
 

PRS-060

  Manage Alerts
Collapse Summary General Information
Company Pieris Pharmaceuticals Inc.
DescriptionAnticalin (class of human binding proteins) targeting interleukin-4 (IL-4) receptor
Molecular Target Interleukin-4 (IL-4) receptor (CD124) (IL-4RA)
Mechanism of ActionInterleukin-4 (IL-4) receptor (CD124) inhibitor
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard IndicationAsthma
Indication DetailsTreat asthma
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/18/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today